NSABP B-43
Disease Stage: 0 (In-situ Disease)
Status: Recruiting patients
Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Title: Clinical Trial Comparing Trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER-2 positive ductal carcinoma in-situ resected by lumpectomy.
Phase: 3
Purpose: To determine the value or trastuzumab given during radiation therapy compared to radiation therapy alone in preventing the subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS.
Eligibility:
- HER-2 positive disease by central testing
- Disease removed by lumpectomy
- No invasive breast cancer
- Good performance status
- Female
Contact: 772-288-5858, option 4
Contact Us
Robert and Carol Weissman Cancer Center
Clinical Research Program
501 E. Osceola St.
Stuart, FL 34994
(772) 288-5858, prompt #4
Email Us